Skip to main content
OpenTrials
Completed

NCT Number: NCT07816575

Comparative Efficacy of Alpha Hydroxy Acids With and Without Nanocarriers Versus Calcipotriol Plus Betamethasone in Treatment of Plaque Psoriasis

The aim of this double blind comparative clinical study is to evaluate the efficacy of AHAs combined with nanocarriers and their use as a non steroidal alternative drug for long term management of plaque psoriasis

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Psoriasis Skin Diseases Skin Diseases, Papulosquamous Skin and Connective Tissue Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Al-Hussien and cairo dermatology Hospital

Cairo, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

- Mid to moderate cases according to Psoriasis Area and Severity Index (PASI).

  • Age from18-65 years old.
  • Denovo psoriatic patients and patients with no psoriasis therapy in the previous two months.

Exclusion criteria

  • Severe irritation and highly inflamed skin.
  • Pregnant and lactating females.
  • Patients with acute renal insufficiency.
  • Face, flexural and groin lesions.

Treatment and study plan

Alpha Hydroxy Acids with nanocarriers

Drug

Topical Alpha Hydroxy Acids formulated with nanocarriers applied to psoriatic plaques.

Alpha Hydroxy Acids only.

Drug

Topical Alpha Hydroxy Acids only applied to psoriatic plaques.

Calcipotriol plus betamethasone

Drug

Topical calcipotriol plus betamethasone ointment applied to psoriatic plaques.

Placebo.

Other

Vehicle control / Placebo topical application applied to psoriatic plaques

Primary outcomes

  1. Percentage Change in PASI Score.

    Time frame: Baseline and 8 weeks

    Reduction in PASI score from baseline to week 8.

Secondary outcomes

  1. Dermatology Life Quality Index (DLQI)

    Time frame: Baseline and 8 weeks).

    Changes in DLQI score to assess the impact of treatment on patients' quality of life.

Other outcomes

  1. Frequency of Adverse Events

    Time frame: Throughout the study period (up to 8 weeks)

    Assessment of any adverse effects related to the applied therapies.

Sponsors and collaborators

Lead sponsor

Al-Azhar University

Other

Registry information

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Sep 11, 2026
Registry last updated
Sep 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.